HALEOSLABS vs SHILPAMED: Stock Comparison

Haleos Labs Limited vs Shilpa Medicare Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Shilpa Medicare Limited is the larger company by market capitalisation. Haleos Labs Limited shows a lower P/E and a higher dividend yield, while Shilpa Medicare Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Shilpa Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 4 of 13 scored metrics and SHILPAMED on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SHILPAMED is the larger company
₹12,013 Cr vs ₹484 Cr
P/E Ratio
HALEOSLABS has a lower P/E
27.94x vs 51.29x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 4.82x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹12.44
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0.08%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs 0%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs 0%
Qtr Sales Growth
SHILPAMED has stronger quarterly sales growth
32.1% vs -15.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSSHILPAMED
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSSHILPAMED
Live Price₹1,522.4₹615.6
Day Change-3.09%-3.81%
Volume2814.89 L
52-Week High₹1,774₹860
52-Week Low₹1,181₹259.5
Distance from 52W High-14.18%-28.42%

Valuation

MetricHALEOSLABSSHILPAMED
Market Cap₹484 Cr₹12,013 Cr
P/E Ratio27.94x51.29x
P/B Ratio2.27x4.82x
EPS₹57.3₹12.44
Book Value₹706₹132.46
Dividend Yield0.1%0.08%

Growth

MetricHALEOSLABSSHILPAMED
Revenue Growth (TTM YoY)0%31.5%
EPS Growth (TTM YoY)0%644.6%
Qtr Sales Growth-15.7%32.1%
Qtr Profit Growth-85.2%148%

Profitability & Leverage

MetricHALEOSLABSSHILPAMED
ROE8.44%9.4%
ROCE9.91%11%
Net Margin5.33%15.82%
Operating Margin13.4%28.2%
Debt to Equity0.52x0.25x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSSHILPAMED
Promoter Holding72.11%40.13%
FII Holding0%11.38% 0.3 pp
DII Holding0.31% 0.01 pp8.05% 0.53 pp
Public Holding27.58% 0.02 pp40.43% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Shilpa Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.